Medial Pharma Limited
About Medial Pharma Limited
Data last updated:
Medial Pharma Limited is a public limited company based in New Delhi, Delhi, India. It operates in the real estate financing segment of the financial services sector. It was incorporated on 09 May 2008 and has been in existence for over 18 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24232DL2008PLC177932. Its GSTIN is 07AAFCM5703Q1Z2 (Delhi).
The company has an authorised share capital of ₹15 Lakh and a paid-up capital of ₹12 Lakh. It is led by directors including Geeta Devi Goel and Jyoti Goyal.
Its last annual general meeting (AGM) was held on 29 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Plot No – 62 Pocket – G Sector – 4 Bawana Dsidc, New Delhi, Delhi, India – 110039.
As per the financials filed for FY 2025, the company reported a revenue of ₹35.17 Lakh, a growth of 21% compared to the previous year. For the same year it recorded a net profit of ₹25.6 Lakh (net margin 72.8%) and EBITDA of ₹32.28 Lakh (EBITDA margin 91.8%). Revenue has grown at a compounded annual rate (CAGR) of 11% over three years and 1% over five years.
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Medial Pharma Limited's registered office is in New Delhi, Delhi. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressPlot No – 62 Pocket – G Sector – 4 Bawana Dsidc, New Delhi, Delhi, India – 110039
- IndustryFinancial Services, Real Estate Financing
To see the full contact details of Medial Pharma Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Financials of Medial Pharma Limited
FY 2025 filings availableMedial Pharma Limited reported revenue of ₹35.17 Lakh (up 21% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 1% over five years, including 21% growth in the latest year. EBITDA rose 21% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹32.28 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹25.6 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 91.8% | ||||
| Net Profit Margin | 72.8% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Medial Pharma Limited, buy the company report.
Board of directors of Medial Pharma Limited
Medial Pharma has 3 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Geeta Devi Goel Also directs: Cogni Pharmaceuticals LLP, Infar Healthcare Private Limited | Director | 06 Jun 2014 | 12 Years 4 Months | Current |
| Jyoti Goyal | Director | 06 Jun 2014 | 12 Years 4 Months | Current |
| Pinki Goel Also directs: Cogni Pharmaceuticals LLP, Infar Healthcare Private Limited | Director | 06 Jun 2014 | 12 Years 4 Months | Current |
Peer comparison
Medial Pharma Limited is compared with the 10 companies closest to it by revenue in the Pharma industry (Formulations), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Wellmatic Healthcare Private Limited | ₹35.55 Lakh (FY 2024) | 188.0% | Patna, Bihar, India | |||
| Torrense Healthcare Private Limited | ₹35.52 Lakh (FY 2021) | 88.0% | Khonagoriyan, Sanganer, Rajasthan, India | |||
| Tenet Bio-Pharma Private Limited | ₹35.38 Lakh (FY 2025) | -85.0% | Jaipur, Rajasthan, India | |||
| Abensia Healthcare Private Limited | ₹35.35 Lakh (FY 2025) | -4.0% | Guwahati, Assam, India | |||
| Newsky Health Pharma Private Limited | ₹35.29 Lakh (FY 2022) | Mumbai, Maharashtra, India | ||||
| Medial Pharma Limitedthis company | ₹35.17 Lakh (FY 2025) | ₹25.6 Lakh | 72.8% | 21.0% | New Delhi, Delhi, India | |
| Ornicon Pharma Private Limited | ₹35.04 Lakh (FY 2025) | 9.0% | Mangalore, Karnataka, India | |||
| Magrig Healthcare Private Limited | ₹35.03 Lakh (FY 2024) | 442.0% | Faridabad, Haryana, India | |||
| Mountmerry Pro International Private Limited | ₹35.01 Lakh (FY 2025) | -53.0% | Jaipur, Rajasthan, India | |||
| Kribss Pharma Private Limited | ₹34.92 Lakh (FY 2022) | 580.0% | Nashik, Maharashtra, India | |||
| Choudhari Drug Distributors Private Limited | ₹34.87 Lakh (FY 2021) | -66.0% | Belgaum, Karnataka, India |
To see the full peer comparison of Medial Pharma Limited, buy the company report.
Auditor
Medial Pharma Limited is audited by DHIRAJ AGGARWAL & ASSOCIATES for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| DHIRAJ AGGARWAL & ASSOCIATES | FY 2023 | 036914N |
Shareholding
The shareholding of Medial Pharma Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Medial Pharma Limited, buy the company report.
Legal cases
No court or tribunal cases involving Medial Pharma Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Medial Pharma Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Medial Pharma has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AAFCM5703Q1Z2 | Delhi | Active | 09 Apr 2019 |
To see the full GST registrations and return filing status of Medial Pharma Limited, buy the company report.
Recent activity
Medial Pharma Limited has 7 board changes on record since 2013: 3 appointments and 4 cessations. The latest: Geeta Devi Goel was appointed as Director on 06 Jun 2014.
Frequently asked questions
Medial Pharma is an active public limited company based in New Delhi, Delhi, India. The company works in real estate financing, within the financial services industry. It was incorporated on 09 May 2008 (18+ years old) and is registered under CIN U24232DL2008PLC177932.
Medial Pharma has 3 current directors:
- Geeta Devi Goel - Director
- Jyoti Goyal - Director
- Pinki Goel - Director
The latest financial statements of Medial Pharma on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 29 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Medial Pharma is 07AAFCM5703Q1Z2, registered in Delhi.
The CIN (Corporate Identification Number) of Medial Pharma is U24232DL2008PLC177932. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Medial Pharma was incorporated on 09 May 2008, making it 18+ years old. It is registered with the Registrar of Companies, Delhi.
The peers of Medial Pharma by revenue are Wellmatic Healthcare Private Limited, Torrense Healthcare Private Limited, Tenet Bio-Pharma Private Limited, Abensia Healthcare Private Limited, Newsky Health Pharma Private Limited and 5 more, all in the Pharma industry (Formulations).
Geeta Devi Goel was appointed as Director on 06 Jun 2014. Jyoti Goyal was appointed as Director on 06 Jun 2014. Mohit Goel ceased to be Additional Director on 06 Jun 2014. Medial Pharma has 7 board changes on record in total.
The registered office of Medial Pharma is at Plot No – 62 Pocket – G Sector – 4 Bawana Dsidc, New Delhi, Delhi, India – 110039.
Medial Pharma operates in the financial services industry, in the real estate financing segment.
The compliance status of Medial Pharma is compliant as of 16 July 2026. The company is actively filing with the Registrar of Companies.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
